Show simple item record

dc.contributor.authorÜstündağ, Mehmet F.
dc.contributor.authorÖzcan, Halil
dc.contributor.authorGencer, Ali G.
dc.contributor.authorYilmaz, Enver D.
dc.contributor.authorUğur, Kerim
dc.contributor.authorOral, Elif
dc.contributor.authorBilici, Mustafa
dc.date.accessioned2020-02-16T14:41:40Z
dc.date.available2020-02-16T14:41:40Z
dc.date.issued2020en_US
dc.identifier.issn0379-5284
dc.identifier.urihttps://hdl.handle.net/11363/1991
dc.descriptionAccession Number: WOS:000508361500006 PubMed ID: 31915793en_US
dc.description.abstractObjectives: To examine the changes in nitric oxide (NO), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-arginine levels in schizophrenia during acute psychotic exacerbation and in bipolar disorder during mania and to compare those changes to healthy controls. Methods: Thirty schizophrenia patients with acute psychotic exacerbation and 30 bipolar disorder patients with mania, who attended the Psychiatry Department, Erenkoy Hospital for Mental and Nervous Diseases, Istanbul, Turkey, in 2010. Thirty healthy controls were included. The diagnosis was made using the Structured Clinical Interview for Axis I Disorders (SCID-I) interviews. Patients' demographic data were recorded, and NO, SDMA, L-arginine, and ADMA levels were studied. Results: Nitric oxide levels in schizophrenia patients were significantly lower than the control group. Nitric oxide levels in the bipolar group were lower than the control group but the difference was not statistically significant. The levels of SDMA, ADMA, and L-arginine were found to be significantly higher in schizophrenia and bipolar disorder patients than the control group. The disease duration was slightly negatively correlated with NO levels in bipolar patients. In schizophrenia patients, the disease severity was slightly positively correlated with NO levels. Conclusion: Significant changes in NO, SDMA, ADMA, and L-arginine levels in schizophrenia and bipolar disorder patients suggest that NO and inhibitors of NO might be implicated in the neurobiology of schizophrenia and bipolar disorder.en_US
dc.language.isoengen_US
dc.publisherSAUDI MED J, ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIAen_US
dc.relation.isversionof10.15537/smj.2020.1.24817en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectSchizophreniaen_US
dc.subjectbipolar disorderen_US
dc.subjectnitric oxideen_US
dc.subjectL-arginineen_US
dc.subjectoxidative stressen_US
dc.subjectDEPRESSIONen_US
dc.subjectNITRATEen_US
dc.subjectRELIABILITYen_US
dc.subjectVALIDITYen_US
dc.subjectPLASMAen_US
dc.subjectADMAen_US
dc.titleNitric oxide, asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in psychotic exacerbation of schizophrenia and bipolar disorder manic episodeen_US
dc.typearticleen_US
dc.relation.journalSAUDI MEDICAL JOURNALen_US
dc.contributor.departmentİktisadi İdari ve Sosyal Bilimler Fakültesien_US
dc.identifier.volume41en_US
dc.identifier.issue1en_US
dc.identifier.startpage38en_US
dc.identifier.endpage45en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess